Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers
暂无分享,去创建一个
S. Paik | Hoguen Kim | E. Shin | Jinseon Yoo | Tae-Min Kim | Hyukmin Lee | J. Ahn | Han Sang Kim | Byung Soh Min | W. Kim | Kyung-A Kim | Chang-gon Kim | Kyungwon Lee | Sang Joon Shin | Han Sang Kim | Won Kyu Kim | Hoguen Kim | S. Shin | Kyungwon Lee
[1] S. Bullman,et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer , 2022, Nature.
[2] Di Wang,et al. Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model , 2022, World journal of gastroenterology.
[3] Yu-qin Mao,et al. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice , 2022, Gut microbes.
[4] H. Qin,et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer , 2021, Signal Transduction and Targeted Therapy.
[5] S. Paik,et al. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer , 2021, Scientific Reports.
[6] O. Mandelboim,et al. Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation , 2021, Frontiers in Cellular and Infection Microbiology.
[7] D. Longley,et al. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC) , 2021, Gut.
[8] C. Huttenhower,et al. Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment , 2021, Clinical Cancer Research.
[9] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[10] J. Galon,et al. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.
[11] E. Elinav,et al. Interaction between microbiota and immunity in health and disease , 2020, Cell Research.
[12] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[13] Liwu Li,et al. Fusobacterium nucleatum host cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration , 2020, bioRxiv.
[14] D. Longley,et al. Fusobacterium nucleatum in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis , 2020, Cancer Epidemiology, Biomarkers & Prevention.
[15] Hoguen Kim,et al. VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers , 2019, Science Immunology.
[16] Kongming Wu,et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.
[17] S. Zhang,et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer , 2019, Journal of experimental & clinical cancer research : CR.
[18] W. Garrett,et al. Fusobacterium nucleatum — symbiont, opportunist and oncobacterium , 2018, Nature Reviews Microbiology.
[19] D. Bending,et al. A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme , 2018, bioRxiv.
[20] Donna Neuberg,et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.
[21] A. York. Microbiome: Fusobacterium persistence in colorectal cancer , 2017, Nature Reviews Microbiology.
[22] Fangfang Guo,et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy , 2017, Cell.
[23] A. Lin,et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma , 2017, Gut.
[24] P. Laurent-Puig,et al. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] S. Paik,et al. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype , 2017, Oncotarget.
[26] Mingyang Song,et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer , 2016, Gut.
[27] M. Hattori,et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.
[28] Etienne Becht,et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.
[29] R. Milo,et al. Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.
[30] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[31] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[32] Mingyang Song,et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.
[33] C. Huttenhower,et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.
[34] J. Meyerhardt,et al. Role of physical activity and diet after colorectal cancer diagnosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] B. Zhu,et al. T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.
[36] P. Goldberg,et al. Quantitative Profiling of Colorectal Cancer-Associated Bacteria Reveals Associations between Fusobacterium spp., Enterotoxigenic Bacteroides fragilis (ETBF) and Clinicopathological Features of Colorectal Cancer , 2015, PloS one.
[37] S. Jonjić,et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. , 2015, Immunity.
[38] S. Ostrand-Rosenberg,et al. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity , 2014, The Journal of Immunology.
[39] Y. Belkaid,et al. Role of the Microbiota in Immunity and Inflammation , 2014, Cell.
[40] Cynthia L Sears,et al. Microbes, microbiota, and colon cancer. , 2014, Cell host & microbe.
[41] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[42] M. R. Rubinstein,et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.
[43] V. Tremaroli,et al. Functional interactions between the gut microbiota and host metabolism , 2012, Nature.
[44] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[45] A. Macpherson,et al. Interactions Between the Microbiota and the Immune System , 2012, Science.
[46] Herman Waldmann,et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.
[47] B. Birren,et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.
[48] Richard A. Moore,et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.
[49] Shuji Ogino,et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.
[50] Susan Kinder-Haake,et al. Fusobacterium nucleatum Outer Membrane Proteins Fap2 and RadD Induce Cell Death in Human Lymphocytes , 2010, Infection and Immunity.